What the label lists and what reports show
Vericiguat side effects
Vericiguat's FDA label: “Most common adverse reactions reported in ≥5% are hypotension and anemia.” FAERS holds 966 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is hypotension (111 reports).
- No generic listed
- Boxed warning
Check it at the source: the vericiguat FDA label on DailyMed (effective January 21, 2026, Merck Sharp & Dohme LLC); the FDA FAERS public dashboard.
What does the patient leaflet say about side effects?
From the patient leaflet: What are the possible side effects of VERQUVO?VERQUVO may cause serious side effects, including: See “What is the most important information I should know about VERQUVO?” The most common side effects of VERQUVO include: low blood pressure low red blood cells (anemia) These are not all the possible side effects of VERQUVO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Source: FDA drug label, NDA214377 (Msd), as published by Merck Sharp & Dohme LLC, effective January 21, 2026 (SPL set 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d), via openFDA; the full label on DailyMed
What does the label list?
From the label: adverse reactionsMost common adverse reactions reported in ≥5% are hypotension and anemia.
From the label: adverse reactions, continuedMost common adverse reactions reported in ≥5% are hypotension and anemia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. VERQUVO was evaluated in VICTORIA, which included 2,519 patients treated with VERQUVO (up to 10 mg once daily). The mean duration of VERQUVO exposure was 1 year, and the maximum duration was 2.6 years [see Clinical Studies (14) ]. Table 1 lists adverse drug reactions occurring more commonly with VERQUVO than placebo and in ≥5% of patients treated with VERQUVO in VICTORIA. Table 1: Adverse Drug Reactions Occurring with VERQUVO in VICTORIA Adverse Drug Reaction VERQUVO % N = 2,519 Placebo % N = 2,515 Hypotension 16 15 Anemia 10 7 VELOCITY The safety and tolerability of VERQUVO 5 mg once daily as a starting dose was evaluated in VELOCITY, a single-arm, open-label, 2-week study in 106 patients with symptomatic chronic heart failure (NYHA class II–IV) and left ventricular ejection fraction < 45%. …
Source: FDA drug label, NDA214377 (Msd), as published by Merck Sharp & Dohme LLC, effective January 21, 2026 (SPL set 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d), via openFDA; the full label on DailyMed
What do FAERS reports show?
966 reports list vericiguat among the medicines taken, each a report of something that happened, not proof the medicine caused it; 148 are coded as a death and 244 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 20 reactions below, 2 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Vericiguat: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions